GenCab: Molecular profiling of tumour pathways determining Cabazitaxel sensitivity and resistance
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms GENCAB
- 07 Sep 2015 Planned End Date changed from 1 Oct 2015 to 1 Aug 2015, as reported by United Kingdom Clinical Research Network record.
- 07 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by United Kingdom Clinical Research Network record.
- 04 Dec 2014 Accrual to date is 20% according to United Kingdom Clinical Research Network.